The Sugar Beat

 
 

  • 'Poised on a Paradigm Shift': The REWIND and DECLARE Trials   Drs Harpreet Bajaj and Akshay Jain, coauthors of the Sugar Beat column, come together to discuss the results and clinical implications of the REWIND and DECLARE trials.
  • CREDENCE Takes SGLT2 Inhibitors 'to the Next Level' What are the clinical implications of the CREDENCE trial? Dr Harpreet Bajaj shares his perspective on this landmark study.
  • Fielding the Dangers of Fasting and Feasting With Diabetes Are you prepared to safely guide your Muslim patients with diabetes through Ramadan, their holy month of fasting? Here's what you need to know.
  • Diabetes 360: A Plan to Quell the 'Tsunami' of Diabetes Diabetes Canada's 360° framework can revolutionize diabetes prevention policies across the globe, says Harpreet Bajaj.
  • Generic DPP-4 Inhibitors Would Be a 'Shot in the Arm' Dr Akshay Jain discusses the potential implications of a generic DPP-4 inhibitor for the management of type 2 diabetes that may soon enter the US market.
  • The Artificial Pancreas Has Arrived in Canada: What to Expect Dr Harpreet Bajaj discusses the first artificial pancreas that has been approved for use in Canada--what to expect, anticipated challenges, and learnings from experiences in the United States.
  • Surviving the Holidays With Diabetes Celebrating the holidays doesn't have to be a choice between losing glycemic control or missing out on the fun. Dr Akshay Jain provides some tips to help guide discussions on safe holiday eating.
  • Dispelling the Myths About Obesity Is obesity a choice? Are people just lazy or suffering from 'food addiction'? Dr Akshay Jain responds to the results of a recent Medscape poll and says it's time to dispel the myths about obesity.
  • SGLT2 Inhibitors: Unreal Primary Prevention? These diabetes drugs offer cardiovascular benefits, but only in diabetes patients who already have CV disease, the author argues.
  • Alcohol Advice Demands Full Disclosure First What do you tell patients who ask about 'safe' alcohol intake--or who inquire about your own drinking habits?
  • CANVAS: Straight Talk Needed on Amputation Risk Can a meta-analysis of two different studies or data from observational studies overcome the clinical concern about the clear-cut amputation risk with canagliflozin seen in the CANVAS trial?